ACH-2928 is Achillion's pan-genotypic NS5A inhibitor, said to have favorable PK for once daily dosing and synergistic with Achillion's portfolio of developmental direct-acting HCV agents.
New Haven drug developer Achillion Pharmaceuticals has launched Phase 1 trials of another treatment for chronic hepatitis just two weeks after starting the next phase of clinical trials on a companion treatment.
Achillion said Monday it has begun trial dosing of ACH-2928, a small-molecule drug for treating the hepatitis C virus.
The U.S. trial involves 48 healthy volunteers 20 patients infected with hepatitis C.
On June 23, Achillion opened Phase 2 of its clinical trial in the U.S. and Europe on 60 patients to test the efficacy and tolerability of its other drug compound, ACH-1625, as an effective treatment for chronic hepatitis.
The bioscience firm has begun dosing 60 patients in the U.S. and Europe for 12 weeks in the second segment of its trial of ACH-1625 for the treatment of hepatitis C virus. Results will be announced in the fourth quarter.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment